檢索結果 - Eric J. Small

Refine Results
  1. 1
    Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma

    Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma 由 Eric J. Small, Ari David Baron, Robert Bok

    出版 1997
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Malignant rhabdoid tumor of the heart in an infant

    Malignant rhabdoid tumor of the heart in an infant 由 Eric J. Small, Beverly Barrett Dahms, Gregory J. Gordon

    出版 1985
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

    A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102 由 George Philips, Susan Halabi, Ben L. Sanford, Dean F. Bajorin, Eric J. Small

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Cancer and Leukemia Group B 90206

    Cancer and Leukemia Group B 90206 由 Brian I. Rini, Susan Halabi, John Taylor, Eric J. Small, Richard L. Schilsky

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Germline and Somatic Mutations in Prostate Cancer for the Clinician

    Germline and Somatic Mutations in Prostate Cancer for the Clinician 由 Heather H. Cheng, Alexandra Sokolova, Edward M. Schaeffer, Eric J. Small, Celestia S. Higano

    出版 2019
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy

    Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer afte... 由 Brian I. Rini, Vivian Weinberg, Lawrence Fong, Shauna Conry, Robert M. Hershberg, Eric J. Small

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer

    Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer 由 Susan Halabi, Nicholas J. Vogelzang, San‐San Ou, Kouros Owzar, Laura Archer, Eric J. Small

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study

    Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Stud... 由 Charles J. Ryan, Susan Halabi, San-San Ou, Nicholas J. Vogelzang, Philip W. Kantoff, Eric J. Small

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma

    A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma 由 William Oh, Susan Halabi, William Kevin Kelly, Cary Werner, Paul A. Godley, Nicholas J. Vogelzang, Eric J. Small

    出版 2003
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients

    Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients 由 Serena S. Kwek, Vinh Dao, Ritu Roy, Yafei Hou, David Alajajian, Jeffrey P. Simko, Eric J. Small, Lawrence Fong

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

    A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma 由 Nancy A. Dawson, Mark Conaway, Susan Halabi, Eric P. Winer, Eric J. Small, Diana Lake, Nicholas J. Vogelzang

    出版 2000
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480

    The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 由 Daniel J. George, Susan Halabi, Timothy F. Shepard, Ben L. Sanford, Nicholas J. Vogelzang, Eric J. Small, Philip W. Kantoff

    出版 2005
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy

    Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy 由 Susan Halabi, Andrew J. Armstrong, Oliver Sartor, Johann S. de Bono, Ellen B. Kaplan, Chen‐Yen Lin, Nicole Solomon, Eric J. Small

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer

    A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer 由 Joel Picus, Susan Halabi, William Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, Eric J. Small

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

    A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma 由 Andrea Harzstark, Eric J. Small, Vivian Weinberg, Janine Sun, Charles J. Ryan, Amy Lin, Lawrence Fong, Dion R. Brocks, Jonathan E. Rosenberg

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

    Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer 由 Susan Halabi, Chen‐Yen Lin, William K. Kelly, Karim Fizazi, Judd W. Moul, Ellen B. Kaplan, Michael J. Morris, Eric J. Small

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer

    Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer 由 Eric J. Small, Mark W. Frohlich, Robert Bok, Katsuto Shinohara, Gary D. Grossfeld, Zinovi Rozenblat, Wm. Kevin Kelly, Michele Corry, David Reese

    出版 2000
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

    CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion 由 Brian D. Kavanagh, Shaun O’Brien, David S. Lee, Yafei Hou, Vivian Weinberg, Brian I. Rini, James P. Allison, Eric J. Small, Lawrence Fong

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients

    Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients 由 Jonathan E. Rosenberg, Vivian Weinberg, William K. Kelly, M. Dror Michaelson, Maha Hussain, George Wilding, Mitchell E. Gross, Douglass Hutcheon, Eric J. Small

    出版 2007
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab

    Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab 由 Serena S. Kwek, Jera Lewis, Li Zhang, Vivian Weinberg, Samantha K. Greaney, Andrea Harzstark, Amy Lin, Charles J. Ryan, Eric J. Small, Lawrence Fong

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: